In a first procedural move of its kind, NCI asked its Board of Scientific Advisors to endorse the institute’s continuing affiliation with the Frederick National Laboratory for Cancer Research, a Federally Funded Research and Development Center.
In this episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher of The Cancer Letter, Jacquelyn Cobb, managing editor, discuss the Sept. 23 meeting of the FDA Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee, during which the panel voted in favor of Galleri, the multi-cancer detection test from GRAIL Inc., to become the first multi-cancer detection test to receive regulatory approval.
